• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 COVID-19 大流行期间,三级成瘾服务机构对阿片类药物依赖的反应。

Response of tertiary addictions services to opioid dependence during the COVID-19 pandemic.

机构信息

Galway-Roscommon Mental Health Services, University Hospital Galway, Galway, Ireland.

National Social Inclusion Office, Mill Lane, Palmerstown, Dublin 20, Ireland.

出版信息

Ir J Psychol Med. 2021 Dec;38(4):301-306. doi: 10.1017/ipm.2021.8. Epub 2021 Feb 4.

DOI:10.1017/ipm.2021.8
PMID:33536093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8503071/
Abstract

The emergence of the COVID-19 pandemic has presented the addiction services with an unprecedented set of challenges. Opioid users are particularly vulnerable because of their high level of pre-existing health problems and lifestyle factors. In order to minimise their risks to self and to others in the current Covid-19 crisis, addiction services sought to urgently identify vulnerable individuals, and induct them into opioid substitution treatment (OST) promptly. Additionally, several guidelines were created and regularly updated by the health and safety executive (HSE) for any healthcare staff working with opioid users. These include guidance documents, to facilitate prompt induction of patients onto the OST programme, the prescribing of naloxone to all patients at risk of overdose, eConsultation, medication management for those in self-isolation, and the delivery of injecting equipment. The guidance documents and resources will provide a template for a new way of working for the sector during these challenging times and into the future.

摘要

COVID-19 大流行的出现给成瘾服务带来了前所未有的一系列挑战。由于阿片类使用者先前存在的健康问题和生活方式因素,他们特别容易受到影响。为了将他们在当前 COVID-19 危机中的自身风险和对他人的风险降到最低,成瘾服务部门试图紧急确定易受感染的个体,并迅速将他们纳入阿片类药物替代治疗 (OST)。此外,卫生和安全执行局 (HSE) 为任何与阿片类使用者合作的医护人员制定并定期更新了几项准则。其中包括指导文件,以促进将患者迅速纳入 OST 计划,向所有有过量用药风险的患者开具纳洛酮处方、电子咨询、自我隔离患者的药物管理以及注射设备的提供。这些指导文件和资源将为该行业在这些充满挑战的时期及未来提供一种新的工作方式模板。

相似文献

1
Response of tertiary addictions services to opioid dependence during the COVID-19 pandemic.在 COVID-19 大流行期间,三级成瘾服务机构对阿片类药物依赖的反应。
Ir J Psychol Med. 2021 Dec;38(4):301-306. doi: 10.1017/ipm.2021.8. Epub 2021 Feb 4.
2
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.全国远程医疗模式评估及在 COVID-19 大流行期间提供阿片类激动剂治疗:报告。
Harm Reduct J. 2020 Jul 17;17(1):49. doi: 10.1186/s12954-020-00394-z.
3
Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.COVID-19大流行期间及之后用于阿片类物质使用障碍的居家注射用阿片类药物亟待解决:一项案例研究
Subst Abuse Treat Prev Policy. 2021 Mar 5;16(1):22. doi: 10.1186/s13011-021-00358-x.
4
Opioid Use Disorder and COVID-19: Crashing of the Crises.阿片类药物使用障碍与 COVID-19:危机的碰撞。
J Addict Med. 2020 Jul/Aug;14(4):e6-e7. doi: 10.1097/ADM.0000000000000684.
5
The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.COVID-19 对使用阿片类药物人群的医疗服务提供的影响:范围综述。
Subst Abuse Treat Prev Policy. 2021 Aug 9;16(1):60. doi: 10.1186/s13011-021-00395-6.
6
Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.在 COVID-19 期间调整减少伤害服务:来自澳大利亚监督注射设施的经验教训。
Harm Reduct J. 2021 Feb 17;18(1):20. doi: 10.1186/s12954-021-00471-x.
7
Buprenorphine Opioid Treatment During the COVID-19 Pandemic.新冠疫情期间的丁丙诺啡阿片类药物治疗
JAMA Intern Med. 2021 Aug 1;181(8):1135. doi: 10.1001/jamainternmed.2021.0777.
8
Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.COVID-19大流行期间的丁丙诺啡阿片类药物治疗——回复
JAMA Intern Med. 2021 Aug 1;181(8):1135-1136. doi: 10.1001/jamainternmed.2021.0774.
9
A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.健康危机中的健康危机:新冠大流行中的阿片类药物获取问题。
Subst Abus. 2021;42(2):148-152. doi: 10.1080/08897077.2021.1900981. Epub 2021 Apr 13.
10
A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.针对患有阿片类物质使用障碍患者的新冠疫情基层医疗应对措施
J Rural Health. 2021 Jan;37(1):169-171. doi: 10.1111/jrh.12438. Epub 2020 Jun 2.

引用本文的文献

1
Impact of guidance issued during COVID-19 to expand take-home doses of opioid agonist treatment (OAT) in Ireland: protocol for a population-based analysis of prescribing practices and patient outcomes 2018 to 2023.新冠疫情期间发布的指南对爱尔兰扩大阿片类激动剂治疗(OAT)带回家剂量的影响:2018年至2023年基于人群的处方实践和患者结局分析方案
HRB Open Res. 2025 Apr 7;8:32. doi: 10.12688/hrbopenres.14044.2. eCollection 2025.
2
Community Pharmacy Needle Exchange Programme: What Can Analysis of the Data Tell Us about the Changing Drug Market in Ireland?社区药房针具交换计划:对爱尔兰不断变化的毒品市场,数据分析能告诉我们什么?
Int J Environ Res Public Health. 2024 Mar 1;21(3):289. doi: 10.3390/ijerph21030289.
3
Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?新冠疫情期间德国阿片类激动剂治疗实践的变化:医生们做了什么,他们希望继续做什么?
Eur Addict Res. 2023;29(5):323-332. doi: 10.1159/000531593. Epub 2023 Aug 9.
4
Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis.爱尔兰阿片类激动剂治疗方案在 COVID-19 大流行期间发生变化,对治疗的可及性和脱落率的影响:一项中断时间序列分析。
J Subst Use Addict Treat. 2023 Jun;149:209029. doi: 10.1016/j.josat.2023.209029. Epub 2023 Mar 31.
5
Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: A national Delphi study.在 COVID-19 大流行期间爱尔兰引入紧急临床指南后,阿片类激动剂治疗的共识建议:一项全国性 Delphi 研究。
Int J Drug Policy. 2022 Aug;106:103768. doi: 10.1016/j.drugpo.2022.103768. Epub 2022 Jun 16.